Marry M Van Den Heuvel-Eibrink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6109338/publications.pdf

Version: 2024-02-01

127 papers

5,776 citations

35 h-index 71 g-index

152 all docs

152 docs citations

152 times ranked

7800 citing authors

#	Article	IF	Citations
1	<scp>MRI</scp> Characteristics of Pediatric Renal Tumors: A <scp>SIOPâ€RTSG</scp> Radiology Panel Delphi Study. Journal of Magnetic Resonance Imaging, 2022, 55, 543-552.	3.4	18
2	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. Haematologica, 2022, 107, 759-764.	3.5	3
3	Characteristics and outcome of children with renal tumors in the Netherlands: The first five-year's experience of national centralization. PLoS ONE, 2022, 17, e0261729.	2.5	10
4	Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy. Cancers, 2022, 14, 943.	3.7	4
5	Oncofertility Perspectives for Girls with Cancer. Journal of Pediatric and Adolescent Gynecology, 2022, 35, 523-526.	0.7	5
6	Renal cell carcinoma in children and adolescents: a retrospective study of a French–Italian series of 93 cases. Histopathology, 2022, 80, 928-945.	2.9	8
7	A Study on Prevalence and Determinants of Ototoxicity During Treatment of Childhood Cancer (SOUND): Protocol for a Prospective Study. JMIR Research Protocols, 2022, 11, e34297.	1.0	0
8	Dexamethasone-Induced Sarcopenia and Physical Frailty in Children With Acute Lymphoblastic Leukemia: Protocol for a Prospective Cohort Study. JMIR Research Protocols, 2022, 11, e33517.	1.0	5
9	Psychosocial developmental milestones of young adult survivors of childhood cancer. Supportive Care in Cancer, 2022, 30, 6839-6849.	2.2	3
10	How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group. Pediatric Blood and Cancer, 2022, 69, e29702.	1.5	9
11	Long-Term Tubular Dysfunction in Childhood Cancer Survivors; DCCSS-LATER 2 Renal Study. Cancers, 2022, 14, 2754.	3.7	0
12	Nutritional Preconditioning in Cancer Treatment in Relation to DNA Damage and Aging. Annual Review of Cancer Biology, 2021, 5, 161-179.	4.5	13
13	Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR Research Protocols, 2021, 10, e21851.	1.0	9
14	Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch) Tj ETQq0 0 0	rgB T./ Øver	loc k 10 Tf 50
15	Outcome of Stage IV Completely Necrotic Wilms Tumour and Local Stage III Treated According to the SIOP 2001 Protocol. Cancers, 2021, 13, 976.	3.7	6
16	Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e45-e56.	10.7	91
17	Clinical and Molecular Characteristics and Outcome of Cystic Partially Differentiated Nephroblastoma and Cystic Nephroma: A Narrative Review of the Literature. Cancers, 2021, 13, 997.	3.7	11
18	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e68-e80.	10.7	37

#	Article	IF	CITATIONS
19	Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e57-e67.	10.7	95
20	Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). Human Reproduction, 2021, 36, 1561-1573.	0.9	20
21	Maternal and Neonatal Outcome after the Use of G-CSF for Cancer Treatment during Pregnancy. Cancers, 2021, 13, 1214.	3.7	11
22	Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours. Nature Communications, 2021, 12, 1407.	12.8	41
23	Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers, 2021, 13, 3142.	3.7	27
24	Single cell derived mRNA signals across human kidney tumors. Nature Communications, 2021, 12, 3896.	12.8	27
25	A comparison of genotyping arrays. European Journal of Human Genetics, 2021, 29, 1611-1624.	2.8	43
26	Recent perspectives on the association between osteonecrosis and bone mineral density decline in childhood acute lymphoblastic leukemia. Faculty Reviews, 2021, 10, 57.	3.9	0
27	Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors. Clinical and Translational Radiation Oncology, 2021, 29, 20-26.	1.7	10
28	TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. Npj Precision Oncology, 2021, 5, 64.	5.4	8
29	Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4734-e4745.	3.6	10
30	Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review. Obesity Reviews, 2021, 22, e13312.	6.5	11
31	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Reports, 2021, 36, 109568.	6.4	25
32	Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group. European Journal of Cancer, 2021, 153, 51-63.	2.8	25
33	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. JAMA Oncology, 2021, 7, 1550.	7.1	14
34	Interobserver variability between experienced and inexperienced observers in the histopathological analysis of Wilms tumors: a pilot study for future algorithmic approach. Diagnostic Pathology, 2021, 16, 77.	2.0	4
35	Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers, 2021, 13, 4598.	3.7	8
36	Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design. BMC Pediatrics, 2021, 21, 427.	1.7	8

#	Article	IF	CITATIONS
37	Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study. Cancers, 2021, 13, 5264.	3.7	10
38	Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors. Neuro-Oncology Advances, 2021, 3, vdab161.	0.7	5
39	Ototoxicity After Childhood Cancer. , 2021, , 27-48.		0
40	Overweight in the Dutch National Cohort of Long-Term Survivors of Childhood Cancer. Blood, 2021, 138, 3054-3054.	1.4	0
41	Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the Literature. Journal of Clinical Medicine, 2021, 10, 5558.	2.4	6
42	Frailty in longâ€ŧerm Dutch adult survivors of childhood acute myeloid leukaemia, neuroblastoma, and Wilms' tumour. JCSM Clinical Reports, 2021, 6, 3-10.	1.3	1
43	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics Journal, 2020, 20, 294-305.	2.0	28
44	Renal cell carcinoma in young FH mutation carriers: case series and review of the literature. Familial Cancer, 2020, 19, 55-63.	1.9	32
45	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer, 2020, 138, 212-224.	2.8	31
46	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 2020, 32, 106227.	1.0	2
47	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers, 2020, 12, 1776.	3.7	29
48	Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4626-e4637.	3 . 6	2
49	Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial). Cancers, 2020, 12, 3745.	3.7	12
50	Hearing and Other Neurologic Problems. Pediatric Clinics of North America, 2020, 67, 1219-1235.	1.8	0
51	Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1397-e1407.	3 . 6	3
52	Renal Tumors of Childhood—A Histopathologic Pattern-Based Diagnostic Approach. Cancers, 2020, 12, 729.	3.7	25
53	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 2020, 11, 1310.	12.8	183
54	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 2020, 12, 1789.	3.7	18

#	Article	IF	CITATIONS
55	Metabolic syndrome detection with biomarkers in childhood cancer survivors. Endocrine Connections, 2020, 9, 676-686.	1.9	10
56	Longitudinal development of cancerâ€related fatigue and physical activity in childhood cancer patients. Pediatric Blood and Cancer, 2019, 66, e27949.	1.5	58
57	Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort. Cancer Causes and Control, 2019, 30, 909-922.	1.8	5
58	Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors. Critical Reviews in Oncology/Hematology, 2019, 133, 129-141.	4.4	44
59	Tinnitus during and after childhood cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2019, 135, 1-7.	4.4	12
60	Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trial. European Journal of Cancer, 2019, 116, 13-20.	2.8	24
61	Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nature Biotechnology, 2019, 37, 303-313.	17. 5	301
62	Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncology, The, 2019, 20, e29-e41.	10.7	90
63	Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. European Journal of Endocrinology, 2019, 181, 173-183.	3.7	12
64	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Research Protocols, 2019, 8, e11868.	1.0	10
65	Reproductive intentions and use of reproductive health care among female survivors of childhood cancer. Human Reproduction, 2018, 33, 1167-1174.	0.9	25
66	Healthâ€related fitness in very longâ€term survivors of childhood cancer: A crossâ€sectional study. Pediatric Blood and Cancer, 2018, 65, e26907.	1.5	10
67	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	7.2	527
68	The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. European Journal of Endocrinology, 2018, 178, 11-22.	3.7	41
69	Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review. Journal of Clinical Oncology, 2018, 36, 2169-2180.	1.6	137
70	Effects of a combined physical and psychosocial training for children with cancer: a randomized controlled trial. BMC Cancer, 2018, 18, 1289.	2.6	37
71	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer, 2018, 18, 930.	2.6	13
72	PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. European Journal of Cancer, 2018, 103, 227-237.	2.8	41

#	Article	IF	Citations
73	The influence of genetic variation on late toxicities in childhood cancer survivors: A review. Critical Reviews in Oncology/Hematology, 2018, 126, 154-167.	4.4	31
74	Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Human Reproduction, 2018, 33, 1474-1488.	0.9	48
75	The long non-coding RNA landscape in juvenile myelomonocytic leukemia. Haematologica, 2018, 103, e501-e504.	3.5	13
76	Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR Research Protocols, 2018, 7, e10824.	1.0	14
77	Congenital mesoblastic nephroma 50 years after its recognition: A narrative review. Pediatric Blood and Cancer, 2017, 64, e26437.	1.5	84
78	Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors. Pediatric Hematology and Oncology, 2017, 34, 120-129.	0.8	35
79	Long-Term Quality of Life in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1218-1226.	3.6	26
80	Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol. Nature Reviews Urology, 2017, 14, 743-752.	3.8	249
81	Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. Thyroid, 2017, 27, 1481-1489.	4.5	16
82	Cost-effectiveness of a combined physical exercise and psychosocial training intervention for children with cancer: Results from the quality of life in motion study. European Journal of Cancer Care, 2017, 26, e12586.	1.5	11
83	Classification of pediatric acute myeloid leukemia based on miRNA expression profiles. Oncotarget, 2017, 8, 33078-33085.	1.8	11
84	Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. European Journal of Cancer, 2016, 69, 77-85.	2.8	72
85	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood, 2016, 127, 1387-1397.	1.4	304
86	Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. Journal of Clinical Oncology, 2016, 34, 3440-3450.	1.6	173
87	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood, 2016, 127, 1163-1172.	1.4	48
88	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. Journal of Clinical Oncology, 2016, 34, 3195-3203.	1.6	105
89	LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates IncRNA H19. Haematologica, 2016, 101, e240-e244.	3.5	18
90	The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia. Haematologica, 2015, 100, 62-69.	3.5	36

#	Article	IF	Citations
91	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood, 2015, 125, 2311-2313.	1.4	60
92	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica, 2015, 100, 17-22.	3.5	43
93	Comment on "Acute lymphoblastic leukemia and adiponcosis" by M. Bifulco and AM Malfitano. Haematologica, 2015, 100, e432-e433.	3.5	1
94	Childhood cancer survivor cohorts in Europe. Acta Oncológica, 2015, 54, 655-668.	1.8	97
95	Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. Journal of Clinical Oncology, 2015, 33, 2999-3007.	1.6	281
96	Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget, 2015, 6, 7232-7243.	1.8	85
97	Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR Cancer, 2015, 1, e11.	2.4	8
98	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	1.4	0
99	<i>RASA4</i> vundergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics, 2014, 9, 1252-1260.	2.7	34
100	Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Haematologica, 2014, 99, 430-436.	3.5	55
101	miR-9 is a tumor suppressor in pediatric AML with t(8;21). Leukemia, 2014, 28, 1022-1032.	7.2	72
102	Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia. Leukemia Research, 2013, 37, 367-371.	0.8	24
103	Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors. European Journal of Cancer, 2013, 49, 668-675.	2.8	24
104	Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer. European Journal of Endocrinology, 2013, 168, 905-912.	3.7	26
105	Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma. European Journal of Cancer, 2012, 48, 1159-1166.	2.8	18
106	A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. BMC Cancer, 2012, 12, 363.	2.6	28
107	Abdominal Radiotherapy: A Major Determinant of Metabolic Syndrome in Nephroblastoma and Neuroblastoma Survivors. PLoS ONE, 2012, 7, e52237.	2.5	59
108	Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer. PLoS ONE, 2012, 7, e43269.	2.5	44

#	Article	IF	CITATIONS
109	Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. Pediatric Blood and Cancer, 2011, 56, 733-737.	1.5	125
110	Prospective Study on Incidence, Risk Factors, and Long-Term Outcome of Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 4143-4150.	1.6	128
111	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. Blood, 2011, 118, 2797-2797.	1.4	0
112	Human Telomere Disease Due to Disruption of the CCAAT Box of the TERC Promoter. Blood, 2011, 118, 2405-2405.	1.4	11
113	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nature Genetics, 2010, 42, 794-800.	21.4	308
114	Molecular basis of juvenile myelomonocytic leukemia. Haematologica, 2010, 95, 179-182.	3.5	53
115	Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncology, The, 2009, 10, 957-966.	10.7	216
116	Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. Pediatric Blood and Cancer, 2008, 50, 1130-1134.	1.5	151
117	Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia Blood, 2008, 112, 1509-1509.	1.4	1
118	Low Frequency of MLL-PTD Detected in Pediatric Acute Myeloid Leukemia Using MLPA Screening Blood, 2008, 112, 1512-1512.	1.4	0
119	CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of Hematology, 2007, 86, 329-337.	1.8	96
120	Nucleophosmin Gene Mutations Identify a Favorable Risk Group in Childhood Acute Myeloid Leukemia with a Normal Karyotype Blood, 2007, 110, 366-366.	1.4	1
121	NF1 Microdeletions in Pediatric MLL-Rearranged AML and T-ALL: A Novel Mechanism for RAS Activation Blood, 2007, 110, 757-757.	1.4	2
122	Differences in Cyto- and Molecular Genetic Abnormalities between Children <2 Years and Older Children with Acute Myeloid Leukemia Blood, 2007, 110, 1830-1830.	1.4	0
123	HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias Blood, 2006, 108, 734-734.	1.4	2
124	Cytogenetics in Pediatric MDS - Data of the EWOG-MDS 98 Study Blood, 2005, 106, 4914-4914.	1.4	0
125	No Evidence for Constitutively Activated FLT3 in Juvenile Myelo-Monocytic Leukemia Blood, 2005, 106, 4915-4915.	1.4	0
126	Intracranial relapse in Wilms tumor patients. Pediatric Blood and Cancer, 2004, 43, 737-741.	1.5	12

MARRY M VAN DEN

#	Article	IF	CITATIONS
127	Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms. Cancer Discovery, 0, , OF1-OF14.	9.4	5